Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study

(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterized by the release of several immune modulators, including Interleukin-6 (IL-6). Tocilizumab (TCZ) is an IL-6 receptor antagonist used to treat rheumatic arthritis. The study aimed to evaluate the effic...

Full description

Bibliographic Details
Main Authors: Wael Hafez, Mohamad Azzam Ziade, Arun Arya, Husam Saleh, Mahmoud Abdelshakor, Osman Fadl Alla, Pragati Agrawal, Sara Ali, Srinivasa Raghu Rao, Subrata Gupta, Ikram Abdelli, Honeymol Sebastian, Mohamed Ali, Muneir Gador, Ziad Al Baha, Ahmed Abdelrahman
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Antibiotics
Subjects:
Tocilizumab
Interlukin-6
thrombosis
COVID-19
SARS-CoV-2
inflammation
Online Access:https://www.mdpi.com/2079-6382/11/2/241

Internet

https://www.mdpi.com/2079-6382/11/2/241

Similar Items